Clinical Trial Update: 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating abiraterone acetate alone or with degarelix, versus degarelix alone, in prostate cancer patients with rising PSA after radical prostate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• degarelix (degarelix)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-11-19